Europe Connected Care Market Report 2025: Connected Care Revenues in Europe to Reach € 17.7 Billion by 2028
The ageing population and the increasing prevalence of chronic diseases will be two of the greatest challenges in Europe during this century. It is widely believed that connected care solutions can ease the burden on society by enabling more efficient delivery of care and allowing people to live independently in their homes for longer. The definition of connected care comprises telecare and telehealth solutions that are used for the remote delivery of healthcare and social care services. Today, the most common connected care solution is the traditional telecare alarm, which includes a wearable alarm button that the user presses in the case of an emergency. Mobile telecare systems have a portable form factor and typically incorporate cellular connectivity and GPS technology. Telehealth solutions involve connected medical devices and monitoring services that are used for the remote monitoring and management of patients with COPD, chronic heart failure, diabetes, hypertension, asthma, coronary heart disease or chronic kidney disease.
Telecare is the largest and most mature segment of the connected care market with a total of 9.0 million users at the end of 2023. The market for telehealth solutions is entering a growth phase with an estimated total of 5.5 million users in the EU 27+3 countries at the end of 2023. The total number of people using connected care solutions amounted to 13.1 million at the end of 2023, as there is an overlap between the two solution categories.
The market is forecasted to grow at a CAGR of 12% during the next five years to reach 23.0 million connected care users by 2028. The publisher expects that telecare will be the largest segment of the connected care market throughout the forecast period reaching 13.1 million users in 2028. Telehealth will follow with 12.5 million users at the end of the forecast period. Connected care revenues in the EU 27+3 countries reached an estimated € 9.4 billion in 2023. This includes revenues from telecare solutions and telehealth solutions.
The market is expected to grow at a CAGR of 13.4 percent between 2023 and 2028 to reach € 17.7 billion at the end of the forecast period. Telehealth solutions accounted for the largest share of the market in 2023 and will remain in lead during the forecast period. The market for telehealth solutions involves a wide range of actors, from specialised equipment vendors to integrated mHealth solution providers. The telecare equipment market in Europe is highly consolidated.
The three major players - Tunstall, Legrand and TeleAlarm - hold leading positions in nearly all markets and together account for about 60 percent of the telecare unit sales in the region. Additional vendors include Careium, Chiptech and Chubb. Chiptech has its operations in the UK market, meanwhile Careium is a leading market player in the Nordic region and has also presence in the UK. Companies such as Telecom Design, Essence Group, 9Solutions, Oysta Technology (Access Group) and Everon are key telecare equipment vendors. Enovation, Skyresponse and Azur Soft are the leading providers of telecare monitoring software solutions.
Additional significant vendors active in Europe are Tellu, Yorbl, Urmet, Navigil, SmartLife Care, Libify, SmartWatcher, Just Checking and Vivago. The telehealth market evolves quickly and many new start-ups as well as well-established solution providers from adjacent industries are active on the market. Examples include Huma, Luscii (Omron Healthcare), Dignio, Comarch, eDevice and SHL Telemedicine. The ongoing digitalisation of telephone networks in Europe requires massive replacements of PSTN-based telecare systems. At the same time, there is rising interest in new types of solutions that enable social care and healthcare services to be delivered more efficiently. The publisher expects that these trends will catalyse the transition to the next generation of connected care solutions.
Future caregiving is also anticipated to be predictive in nature by continuously analysing user data and acting on abnormalities. Care providers will work with solutions that rely on data not only from telecare devices, but also from other sources such as smart home sensors and healthcare records. Artificial intelligence (AI) is also rapidly becoming a cornerstone of modern healthcare practices, driving improvements in clinical efficiency, patient engagement and care coordination. The transition to digital technologies is good news for mobile network operators, as many connected care systems rely on cellular connectivity. The number of cellular connections is predicted to grow from around 7.8 million in 2023 to more than 14.8 million in 2028.
This report will allow you to
Profit from 30 executive interviews with market leading companies.
Identify key players in the connected care ecosystem.
Learn about the latest developments in connected care devices and services.
Understand the dynamics of the European healthcare and social care systems.
Evaluate how the adoption of next-generation solutions is proceeding.
Benefit from expert market analysis including detailed market forecasts lasting until 2028.
The report answers the following questions
Which are the main verticals within connected care?
What are the main drivers on this market in Europe?
How many people are using telecare systems in each European country?
Which are the leading telecare equipment providers in Europe?
How will the connected care market evolve in the next five years?
What are the general technology trends for connected care products?
How will the markets for telehealth, telecare and smart home solutions converge?
What is the potential market size for cellular IoT connectivity?
Key Topics Covered:
1 Healthcare and Social Care in Europe
1.1 Introduction
1.1.1 The ageing population
1.1.2 Metabolic syndrome and lifestyle-related diseases
1.2 Chronic diseases
1.2.1 Cardiovascular diseases
1.2.2 Chronic respiratory diseases
1.2.3 Diabetes
1.3 Neurological disorders, mental disorders and physical disabilities
1.3.1 Autism spectrum disorders
1.3.2 Dementia
1.3.3 Epilepsy
1.3.4 Other disorders and disabilities
1.4 Healthcare and social care systems
1.4.1 Healthcare systems
1.4.2 Social care systems
1.5 The regulatory environment
1.5.1 Medical device regulations
1.5.2 Privacy regulations
1.5.3 Standardisation
2 Telecare Solutions
2.1 Market overview
2.2 Solution providers
9Solutions
Access Group (Oysta Technology)
Althea
Appello
Azur Soft
Beghelli
Buddi (Big Technologies)
Careium
Chiptech
Chubb Community Care
Enovation (Legrand Care)
Essence Group
Eurocross Assistance
Everon
Genus Care
James TeleCare (iLogs Healthcare)
Just Checking
Legrand Care
Libify
Limmex
MetAlert (GTX Corp)
MiniFinder
Navigil
Nobi
Posifon
Sensio Group
Skyresponse
SmartLife Care
Smartwatcher
TeleAlarm Group
Telecom Design
Telegrafik
Tellu
Tunstall Healthcare Group
Urmet ATE
Vitakt Hausnotruf
Vivago
VIVAI Software
Yorbl
Zembro
3 Telehealth Solutions
3.1 Market overview
3.1.1 Form factors and use cases
3.1.2 Value chain
3.1.3 Competitive landscape
3.1.4 The European telehealth landscape by country
3.2 Solution providers
Ab Medica
Alira Health (Bepatient)
Alphabet
Apple
Aptar Digital Health
BT Group
Comarch Healthcare
Dignio
Doccla (Open TeleHealth)
eDevice
Hope Care
Huma Therapeutics
KPN
Luscii (Omron Healthcare)
Medixine
MedM
S3 Connected Health
SHL Telemedicine
SiDLY
Telefonica
Vitagroup
4 Market Forecasts and Conclusions
4.1 Market trends and analysis
4.1.1 PSTN switch off continues to drive the transition to IP-based telecare
4.1.2 The role of AI in transforming connected care solutions
4.1.3 BYOD has become a common option for telehealth
4.1.4 Technological developments change the competitive landscape
4.1.5 Integrated data systems are becoming increasingly important
4.1.6 The digital shift will unlock new services and use cases
4.1.7 Convergence between telecare and telehealth towards integrated care
4.1.8 Advancing remote care with data-driven strategies
4.1.9 The use of mobile telecare solutions grows rapidly
4.1.10 A slowly awakening consumer market for telecare in Europe
4.1.11 Staffing shortages is a catalyst for digital transformation
4.1.12 Technology enabled care enables elderly to age at home for longer
4.1.13 COVID-19 became a catalyst that took telehealth into the next growth phase
4.2 Market forecasts
4.3 Revenue forecasts
For more information about this report visit https://www.researchandmarkets.com/r/kud77y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: EUROPE
Copyright Business Wire 2025.
PUB: 02/24/2025 07:20 AM/DISC: 02/24/2025 07:24 AM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
5 hours ago
- CNBC
Beijing's tussle with Brussels: China retaliates on EU medical devices
CNBC's Chery Kang and Elaine Yu discuss what China's move to impose reciprocal tariffs on the import of medical devices from the European Union could mean for an upcoming EU-China summit later this month.
Yahoo
21 hours ago
- Yahoo
Weedkiller ingredient widely used in US can damage organs and gut bacteria, research shows
The herbicide ingredient used to replace glyphosate in Roundup and other weedkiller products can kill gut bacteria and damage organs in multiple ways, new research shows. The ingredient, diquat, is widely employed in the US as a weedkiller in vineyards and orchards, and is increasingly sprayed elsewhere as the use of controversial herbicide substances such as glyphosate and paraquat drops in the US. But the new piece of data suggests diquat is more toxic than glyphosate, and the substance is banned over its risks in the UK, EU, China and many other countries. Still, the EPA has resisted calls for a ban, and Roundup formulas with the ingredient hit the shelves last year. Related: 'We thought we'd got the numbers wrong': how a pristine lake came to have the highest levels of 'forever chemicals' on record 'From a human health perspective, this stuff is quite a bit nastier than glyphosate so we're seeing a regrettable substitution, and the ineffective regulatory structure is allowing it,' said Nathan Donley, science director with the Center For Biological Diversity, which advocates for stricter pesticide regulations but was not involved in the new research. 'Regrettable substitution' is a scientific term used to describe the replacement of a toxic substance in a consumer product with an ingredient that is also toxic. Diquat is also thought to be a neurotoxin, carcinogen and linked to Parkinson's disease. An October analysis of EPA data by the Friends of the Earth non-profit found it is about 200 times more toxic than glyphosate in terms of chronic exposure. Bayer, which makes Roundup, faced nearly 175,000 lawsuits alleging that the product's users were harmed by the product. Bayer, which bought Monsanto in 2018, reformulated Roundup after the International Agency for Research on Cancer classified glyphosate as a possible carcinogen. The new review of scientific literature in part focuses on the multiple ways in which diquat damages organs and gut bacteria, including by reducing the level of proteins that are key pieces of the gut lining. The weakening can allow toxins and pathogens to move from the stomach into the bloodstream, and trigger inflammation in the intestines and throughout the body. Meanwhile, diquat can inhibit the production of beneficial bacteria that maintain the gut lining. Damage to the lining also inhibits the absorption of nutrients and energy metabolism, the authors said. The research further scrutinizes how the substance harms the kidneys, lungs and liver. Diquat 'causes irreversible structural and functional damage to the kidneys' because it can destroy kidney cells' membranes and interfere with cell signals. The effects on the liver are similar, and the ingredient causes the production of proteins that inflame the organ. Meanwhile, it seems to attack the lungs by triggering inflammation that damages the organ's tissue. More broadly, the inflammation caused by diquat may cause multiple organ dysfunction syndrome, a scenario in which organ systems begin to fail. The authors note that many of the studies are on rodents and more research on low, long-term exposure is needed. Bayer did not immediately respond to a request for comment. Despite the risks amid a rise in diquat's use, the EPA is not reviewing the chemical, and even non-profits that push for tighter pesticide regulations have largely focused their attention elsewhere. Donley said that was in part because US pesticide regulations are so weak that advocates are tied up with battles over ingredients like glyphosate, paraquat and chlorpyrifos – substances that are banned elsewhere but still widely used here. Diquat is 'overshadowed' by those ingredients. 'Other countries have banned diquat, but in the US we're still fighting the fights that Europe won 20 years ago,' Donley said. 'It hasn't gotten to the radar of most groups and that really says a lot about the sad and sorry state of pesticides in the US.' Some advocates have accused the EPA of being captured by industry, and Donley said US pesticide laws were so weak that it was difficult for the agency to ban ingredients, even if the will exists. For example, the agency banned chlorpyrifos in 2022, but a court overturned the decision after industry sued. Moreover, the EPA's pesticides office seems to have a philosophy that states that toxic pesticides are a 'necessary evil', Donley said. 'When you approach an issue from that lens there's only so much you will do,' he said.
Yahoo
a day ago
- Yahoo
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
